Display Settings:

Format

Send to:

Choose Destination

    Ann Intern Med. 1981 Apr;94(4 pt 1):472-4.

    Increased clearance of propranolol in thyrotoxicosis.

    Feely J, Stevenson IH, Crooks J.

    The pharmacokinetics of oral propranolol were studied during chronic treatment in six patients when thyrotoxic and again when euthyroid. The mean total plasma propranolol steady-state concentration was 42% lower when the patients were thyrotoxic. After treatment of thyrotoxicosis there was a fall (P less than 0.05) in the oral clearance of both total (4.2 +/- 0.6 to 2.7 +/- 0.4 L/min, mean +/- SEM) and free (30.5 +/- 4.7 to 25.5 +/- 4.1 L/min) propranolol although the half-life of propranolol did not change significantly. The free fraction of propranolol was higher (p less than 0.05) in the thyrotoxic (14.2% +/- 1.3%) than in the euthyroid (11.4% +/- 0.8%) state. These results suggest that the pharmacokinetics of propranolol are significantly altered in thyrotoxicosis.

    PMID: 7212504 [PubMed - indexed for MEDLINE]

    LinkOut - more resources

    Full Text Sources:

    Molecular Biology Databases:

    Supplemental Content

    Patient drug information

    • Propranolol Oral (Inderal®, Inderal® LA, Inderide®, ...)

      Propranolol is used to treat high blood pressure, abnormal heart rhythms, heart disease, pheochromocytoma (tumor on a small gland near the kidneys), and certain types of tremor. It is also used to prevent angina (chest p...